Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

Faron Pharma to provide drug compassionate use of drug; data monitors green light study as it moves into its final few months

The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Clinical Trial
Faron plans to treat 300 ARDS patients with Traumakine

Faron Pharmaceuticals Ltd (LON:FARN) said it is planning to provide its lead drug on a compassionate use basis once its phase III clinical trial has concluded.

The study, codenamed INTEREST, should be wrapped up in the fourth-quarter.

It was set up to assess the efficacy of Traumakine in treating acute respiratory distress syndrome (ARDS).

Faron said in its latest release that the independent data monitoring committee (IMDC) overseeing the clinical investigation has said the trial should continue unchanged.

Unment medical need

This is consistent with its four previous recommendations.

Faron plans to treat 300 ARDS patients with Traumakine, which performed well in an earlier phase II clinical study.

ARDS is severe lung condition that often results from pneumonia and has mortality rate of 30-45% with 300,000 cases annually in Europe and the US.

"We are very pleased to receive the IDMC's recommendation that the INTEREST study should continue as planned,” said Faron chief executive, Dr Markku Jalkanen.

“The trial is now moving into its final stages and we look forward to closing recruitment during the fourth quarter of 2017.”

'Cleva'  approach

Faron’s pipeline also includes a Clevegen, a pre-clinical drug designed uses the body’s own immune system to tackle cancer.

As the name suggests it does something new and clever that marks out from all the other immuno-oncology treatments coming out of the lab and into early trials.

Consisting of anti-Clever-1 antibody it converts the immune environment around a tumour from being suppressive to immune stimulating.

WATCH: Markku Jalkanen 'excited' to be advancing Clevegen

View full FARN profile View Profile

Faron Pharmaceuticals Ltd Timeline

September 12 2018

Related Articles

August 21 2018
The company aims to revolutionise the HPA production process, eschewing the laborious bauxite-sourced method.
June 04 2018
While tricky, the last year has seen Abzena increase its customer engagement with its integrated discovery, development and manufacturing service offering
3d rendering of an antibody
July 24 2018
It is teaming up with Bach BioSciences, a company commercialising the research of William Bachovchin, a professor at Tufts University School of Medicine, Boston

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use